Women with atrial fibrillation: Greater risk, less attention

Gender Medicine

Volumn 6, Issue 3, 2009, Pages 419-432

  Volgman, Annabelle S ^a   Manankil, Marian F ^a   Mookherjee, Disha ^a   Trohman, Richard G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

arrhythmias; atrial fibrillation; gender; women

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; AZIMILIDE; C REACTIVE PROTEIN; DOFETILIDE; ESTROGEN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; IRBESARTAN; PRAVASTATIN; PROGESTERONE; PROPAFENONE; SOTALOL; THROMBIN INHIBITOR; WARFARIN;

ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; BLEEDING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EATING DISORDER; ELECTROLYTE DISTURBANCE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HUMAN; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK REDUCTION; SELF MONITORING; SEX DIFFERENCE; THROMBOEMBOLISM; TORSADE DES POINTES; WOMEN'S HEALTH;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAM PATTERN; FEMALE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; WOMEN'S HEALTH;

EID: 70350070299     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2009.09.008     Document Type: Review

References (84)

1. American Heart Association. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. http://www.americanheart.org/presenter.jhtml?identifier=3054076 Accessed August 5, 2009
2. Fang M.C., Singer D.E., Chang Y., et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 112 (2005) 1687-1691
3. Falk R.H. Atrial fibrillation [published correction appears in N Engl J Med. 2001;344:1876]. N Engl J Med. 344 (2001) 1067-1078
4. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 98 (1998) 946-952
5. Kaufman E.S., Zimmermann P.A., Wang T., et al., the Atrial Fibrillation Follow-up Investigation of Rhythm Management Investigators. Risk of proar-rhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: A multivariate analysis. J Am Coll Cardiol. 44 (2004) 1276-1282
6. Kerr C.R., and Humphries K. Gender-related differences in atrial fibrillation. J Am Coll Cardiol. 46 (2005) 1307-1308
7. Paeratakul S., Lovejoy J.C., Ryan D.H., and Bray G.A. The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes Relat Metab Disord. 26 (2002) 1205-1210
8. Umetani K., Kodama Y., Nakamura T., et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 71 (2007) 252-255
9. Frost L., Hune L.J., and Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med. 118 (2005) 489-495
10. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 292 (2004) 2471-2477
11. Zacharias A., Schwann T.A., Riordan C.J., et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 112 (2005) 3247-3255
12. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 108 (2003) 3006-3010
13. Sata N., Hamada N., Horinouchi T., et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation?. Jpn Heart J. 45 (2004) 441-445
14. Dernellis J., and Panaretou M. Relationship between C-reactive protein concentrations during gluco-corticoid therapy and recurrent atrial fibrillation. Eur Heart J. 25 (2004) 1100-1107
15. Halonen J., Halonen P., Järvinen O., et al. Cortico-steroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA. 297 (2007) 1562-1567
16. Hogue Jr. C.W., Palin C.A., Kailasam R., et al. C-reactive protein levels and atrial fibrillation after cardiac surgery in women. Ann Thorac Surg. 82 (2006) 97-102
17. Hobbs W.L., and Johnson C.A. Anorexia nervosa: An overview. Am Fam Physician. 54 (1996) 1273-1279
18. Hobbs W.L., and Johnson C.A. Anorexia nervosa: An overview. Am Fam Physician. 54 (1996) 1284-1286
19. Kollai M., Bonyhay I., Jokkel G., and Szonyi L. Cardiac vagal hyperactivity in adolescent anorexia nervosa. Eur Heart J. 15 (1994) 1113-1118
20. Mizuno R., Fujimoto S., Kimura Y., et al. Anorexia nervosa with left atrial failure. Intern Med. 37 (1998) 857-860
21. Gupta A., Lawrence A.T., Krishnan K., et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 153 (2007) 891-899
22. Mäki T., Toivonen L., Koskinen P., et al. Effect of ethanol drinking, hangover, and exercise on adrenergic activity and heart rate variability in patients with a history of alcoholinduced atrial fibrillation. Am J Cardiol. 82 (1998) 317-322
23. Djoussé L., Levy D., Benjamin E.J., et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol. 93 (2004) 710-713
24. Frost L., and Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: A cohort study. Arch Intern Med. 164 (2004) 1993-1998
25. Mukamal K.J., Tolstrup J.S., Friberg J., et al. Alcohol consumption and risk of atrial fibrillation in men and women: The Copenhagen City Heart Study. Circulation. 112 (2005) 1736-1742
26. Conen D., Tedrow U.B., Cook N.R., et al. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA. 300 (2008) 2489-2496
27. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 271 (1994) 840-844
28. Eaker E.D., Sullivan L.M., Kelly-Hayes M., et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation. 109 (2004) 1267-1271
29. Eaker E.D., Sullivan L.M., Kelly-Hayes M., et al. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: The Framingham Offspring Study. Psychosom Med. 67 (2005) 692-696
30. Humphries K.H., Kerr C.R., Connolly S.J., et al. Newonset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation. 103 (2001) 2365-2370
31. Hnatkova K., Waktare J.E., Murgatroyd F.D., et al. Age and gender influences on rate and duration of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 21 (1998) 2455-2458
32. Khairy P., and Nattel S. New insights into the mechanisms and management of atrial fibrillation. CMAJ. 167 (2002) 1012-1020
33. Paquette M., Roy D., Talajic M., et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 86 (2000) 764-768
34. Ong L., Irvine J., Nolan R., et al. Gender differences and quality of life in atrial fibrillation: The mediating role of depression. J Psychosom Res. 61 (2006) 769-774
35. Rienstra M., Van Veldhuisen D.J., Hagens V.E., et al., the RACE Investigators. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: Data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 46 (2005) 1298-1306
36. Essebag V., Hadjis T., Platt R.W., and Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol. 41 (2003) 249-254
37. Curtis A.B., Gersh B.J., Corley S.D., et al., the AFFIRM Investigators. Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 149 (2005) 645-649
38. Pilote L., Dasgupta K., Guru V., et al. A comprehensive view of sex-specific issues related to cardiovascular disease [published correction appears in CMAJ. 2007;176:1310]. CMAJ. 176 (2007) S1-S44
39. Gowda R.M., Khan I.A., Punukollu G., et al. Female preponderance in ibutilide-induced torsades de pointes. Int J Cardiol. 95 (2004) 219-222
40. Lehmann M.H., Hardy S., Archibald D., et al. Sex difference in risk of torsades de pointes with d,l-sotalol. Circulation. 94 (1996) 2535-2541
41. Makkar R.R., Fromm B.S., Steinman R.T., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 270 (1993) 2590-2597
42. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 321 (1989) 406-412
43. Echt D.S., Liebson P.R., Mitchell L.B., et al., the Cardiac Arrhythmia Suppression Trial. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 324 (1991) 781-788
44. Green D.M., Ropper A.H., Kronmal R.A., et al., the Cardiac Arrhythmia Suppression Trial. Cardiovascular Health Study. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology. 59 (2002) 314-320
45. Lehmann M.H., Hardy S., Archibald D., and MacNeil D.J. JTc prolongation with d,l-sotalol in women versus men. Am J Cardiol. 83 (1999) 354-359
46. Jochmann N., Stangl K., Garbe E., et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 26 (2005) 1585-1595
47. Pratt C.M., Camm A.J., Cooper W., et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: Why did patients die?. Am J Cardiol. 81 (1998) 869-876
48. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al., the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 341 (1999) 857-865
49. Rodriguez I., Kilborn M.J., Liu X.K., et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 285 (2001) 1322-1326
50. Burke J.H., Ehlert F.A., Kruse J.T., et al. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol. 79 (1997) 178-181
51. Nakagawa M., Ooie T., Takahashi N., et al. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol. 29 (2006) 607-613
52. Rashba E.J., Zareba W., Moss A.J., et al., the LQTS Investigators. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation. 97 (1998) 451-456
53. Kadish A.H., Greenland P., Limacher M.C., et al. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol. 9 (2004) 366-374
54. Wysowski D.K., Kornegay C., Nourjah P., and Trontell A. Sex and age differences in serum potassium in the United States. Clin Chem. 49 (2003) 190-192
55. Wahr J.A., Parks R., Boisvert D., et al., the Multicenter Study of Perioperative Ischemia Research Group. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. JAMA. 281 (1999) 2203-2210
56. Fuster V., Rydén L.E., Asinger R.W., et al., the American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 38 (2001) 1231-1266
57. Hurd II H.P., Palumbo P.J., and Gharib H. Hypothalamic-endocrine dysfunction in anorexia nervosa. Mayo Clin Proc. 52 (1977) 711-716
58. Borini P., Terrazas J.H., Ferreira Junior A., et al. Female alcoholics: Electrocardiographic changes and associated metabolic and electrolytic disorders. Arq Bras Cardiol. 81 (2003) 506-517
59. Lorsheyd A., de Lange D.W., Hijmering M.L., et al. PR and QTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals [published correction appears in Neth J Med. 2005;63:136]. Neth J Med. 63 (2005) 59-63
60. Wolf P.A., Mitchell J.B., Baker C.S., et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 158 (1998) 229-234
61. Gomberg-Maitland M., Wenger N.K., Feyzi J., et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 27 (2006) 1947-1953
62. Carandang R., Seshadri S., Beiser A., et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 296 (2006) 2939-2946
63. Dagres N., Nieuwlaat R., Vardas P.E., et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 49 (2007) 572-577
64. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 285 (2001) 2370-2375
65. Warfarin versus aspirin for prevention of throm-boembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 343 (1994) 687-691
66. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 348 (1996) 633-638
67. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation. 110 (2004) 2287-2292
68. Connock M., Stevens C., Fry-Smith A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: A systematic review and economic modelling. Health Technol Assess. 11 (2007) iii-iv
69. Connock M., Stevens C., Fry-Smith A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: A systematic review and economic modelling. Health Technol Assess. 11 (2007) ix-66
70. Kulinna W., Ney D., Wenzel T., et al. The effect of self-monitoring the INR on quality of anticoagulation and quality of life. Semin Thromb Hemost. 25 (1999) 123-126
71. Galinier M., Pathak A., and Roncalli J. Angiotensin receptor blockers and cardiac rhythm disorders [in French]. Arch Mal Coeur Vaiss. 99 (2006) 745-747
72. Enriquez J.R., Pratap P., Zbilut J.P., et al. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med. 5 (2008) 53-61
73. Amar D., Zhang H., Heerdt P.M., et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest. 128 (2005) 3421-3427
74. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 114 (2006) 1455-1461
75. Tveit A., Grundtvig M., Gundersen T., et al. Analysis of pravastatin to prevent recurrence of atrial fibril-lation after electrical cardioversion. Am J Cardiol. 93 (2004) 780-782
76. Patel A.A., White C.M., Shah S.A., et al. The relationship between statin use and atrial fibrillation. Curr Med Res Opin. 23 (2007) 1177-1185
77. Roy D., Talajic M., Nattel S., et al., the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 358 (2008) 2667-2677
78. Fisher J.D., Spinelli M.A., Mookherjee D., et al. Atrial fibrillation ablation: Reaching the mainstream. Pacing Clin Electrophysiol. 29 (2006) 523-537
79. Forleo G.B., Tondo C., De Luca L., et al. Gender-related differences in catheter ablation of atrial fibrillation. Europace. 9 (2007) 613-620
80. Connolly S.J., Pogue J., Hart R.G., and the ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 360 (2009) 2066-2078
81. Verma A.K., and Brighton T.A. The direct factor Xa inhibitor rivaroxaban. Med J Aust. 190 (2009) 379-383
82. Glynn R.J., Danielson E., Fonseca F.A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 360 (2009) 1851-1861
83. Fountain R.B., Holmes D.R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J. 151 (2006) 956-961
84. Hohnolser S.H., Crijns H.J., van Eickels M., et al., the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation [published correction appears in N Engl J Med. 2009; 360:2487]. N Engl J Med. 360 (2009) 668-678